» Articles » PMID: 19110058

MicroRNA Regulation of Alzheimer's Amyloid Precursor Protein Expression

Overview
Journal Neurobiol Dis
Specialty Neurology
Date 2008 Dec 27
PMID 19110058
Citations 205
Authors
Affiliations
Soon will be listed here.
Abstract

Gene dosage effects of Amyloid precursor protein (APP) can cause familial AD. Recent evidence suggest that microRNA (miRNA) pathways, implicated in gene transcriptional control, could be involved in the development of sporadic Alzheimer's disease (AD). We therefore investigated whether miRNAs could participate in the regulation of APP gene expression. We show that miRNAs belonging to the miR-20a family (that is, miR-20a, miR-17-5p and miR-106b) could regulate APP expression in vitro and at the endogenous level in neuronal cell lines. A tight correlation between these miRNAs and APP was found during brain development and in differentiating neurons. We thus identify miRNAs as novel endogenous regulators of APP expression, suggesting that variations in miRNA expression could contribute to changes in APP expression in the brain during development and disease. This possibility is further corroborated by the observation that a statistically significant decrease in miR-106b expression was found in sporadic AD patients.

Citing Articles

Coenzyme Q10 alleviates AlCl and D-galactose induced Alzheimer via modulating oxidative burden and TLR-4/MAPK pathways and regulation microRNA in rat brain.

Nawar N, Beltagy D, Tousson E, El-Keey M, Mohamed T Toxicol Res (Camb). 2025; 14(2):tfaf031.

PMID: 40052020 PMC: 11881693. DOI: 10.1093/toxres/tfaf031.


An Update on Neuroaging on Earth and in Spaceflight.

Kuznetsov N, Statsenko Y, Ljubisavljevic M Int J Mol Sci. 2025; 26(4).

PMID: 40004201 PMC: 11855577. DOI: 10.3390/ijms26041738.


Non-coding RNAs in the pathogenesis of Alzheimer's disease: β-amyloid aggregation, Tau phosphorylation and neuroinflammation.

Jimenez-Ramirez I, Castano E Mol Biol Rep. 2025; 52(1):183.

PMID: 39890684 DOI: 10.1007/s11033-025-10284-x.


Advancements in nose-to-brain drug targeting for Alzheimer's disease: a review of nanocarriers and clinical insights.

Komal K, Ghosh R, Sil D, Sharma R, Kumar S, Pandey P Inflammopharmacology. 2025; 33(2):605-626.

PMID: 39776027 DOI: 10.1007/s10787-024-01636-3.


Exosomal MicroRNAs in Alzheimer's Disease: Unveiling Their Role and Pioneering Tools for Diagnosis and Treatment.

Alhenaky A, Alhazmi S, Alamri S, Alkhatabi H, Alharthi A, Alsaleem M J Clin Med. 2024; 13(22).

PMID: 39598105 PMC: 11594708. DOI: 10.3390/jcm13226960.